<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25212">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02104414</url>
  </required_header>
  <id_info>
    <org_study_id>13-0062</org_study_id>
    <nct_id>NCT02104414</nct_id>
  </id_info>
  <brief_title>Efficacy of Rectal Infiltration of Exparel for Analgesic Benefit Following Hemorrhoidectomy</brief_title>
  <official_title>Comparison of Rectal Infiltration of Exparel vs. 0.25% Bupivacaine With Epinephrine vs. Placebo for Analgesic Benefit Following Hemorrhoidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the quality and duration of pain relief after a
      hemorrhoidectomy, provided by locally administered liposomal bupivacaine versus bupivacaine
      hcl or control with saline. It is hypothesized that liposomal bupivacaine will provide more
      effective postoperative pain relief than both bupivacaine hcl and the control.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Post operative pain control</measure>
    <time_frame>The first 96 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary objective is to evaluate analgesia following local infiltration of 30 mL Exparel or the same volume of 0.25% bupivacaine HCl with epinephrine or normal saline. The intensity of pain will be measured using a numerical rating scale (NRS-11) in which 0 represents no pain, and 10 represents extreme pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>Hourly from PACU arrival to discharge and Q4H from 10:00-22:00 postoperatively for 4 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>Hourly from PACU arrival to discharge and Q4H from 10:00-22:00 postoperatively for 4 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of and pain during postoperative bowel movements</measure>
    <time_frame>Hourly from PACU arrival to discharge and Q4H from 10:00-22:00 postoperatively for 4 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of urinary retention</measure>
    <time_frame>Hourly from PACU arrival to discharge and Q4H from 10:00-22:00 postoperatively for 4 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hemorrhoid</condition>
  <arm_group>
    <arm_group_label>Exparel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>266mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCl with epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75mg/30mL 0.25% Bupivacaine HCl with epinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30mL Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>266 mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)</description>
    <arm_group_label>Exparel</arm_group_label>
    <other_name>Liposomal Bupivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl with Epinephrine</intervention_name>
    <description>75mg/30mL 0.25% Bupivacaine HCl with epinephrine</description>
    <arm_group_label>Bupivacaine HCl with epinephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>30mL Normal Saline</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing hemorrhoidectomy for grade 3 or 4 hemorrhoids who are
             English-speaking patients, 21-65 yr of age, ASA physical status I-III, BMI&lt;30

        Exclusion Criteria:

          -  contraindications to administration of local anesthesia (e.g., local anesthetic
             allergy), difficult airway (Mallampati&gt;2), psychiatric or cognitive disorders,
             pregnancy , and history of substance abuse or chronic opioid use
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Shariat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ali Shariat, MD</last_name>
    <phone>914-409-5023</phone>
    <email>alishariatmd@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St.Luke's-Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ali Shariat, MD</last_name>
      <phone>914-409-5023</phone>
      <email>alishariatmd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ali Shariat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Admir Hadzic, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nipa Gandhi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>March 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liposomal Bupivacaine</keyword>
  <keyword>Exparel</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
